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analysis was 90%.
We initially compared single parameters of PFTs including
corrected diffusion limiting capacity of oxygen (DLCO), forced
expiratory volume in one second (FEV1), forced vital capacity
(FVC), FEV1/FVC ratio, and total lung capacity (TLC) obtained
before and after transplant. Post transplant, all PFT parame-
ters showed some degree of reduction compared to pre-
transplant values. FEV1 and FEV1/FVC were signiﬁcantly
decreased (108 vs 92, P ¼ .04 and 86 vs 80%, P ¼ .04, respec-
tively), with no difference between Caucasian and non-
Caucasians. Overall, median values of corrected DLCOand TLC
prior to and after transplant were only slightly reduced.
However, in non-Caucasian patients a signiﬁcant reduction of
DLCO was observed (93%31 vs 73%11, P ¼ .05).
We analyzed intra-patient changes in DLCO and FEV1 values
and no correlationwas found between these parameters and
the development of chronic GVHD.
This study shows an overall decrease in pulmonary function
in patients without apparent lung disease following a mye-
loablative busulfan-based HSCT. However, a higher risk of
a reduced DLCO was noted only among non-Caucasian
patients. At this time it is not known if this observation is due
to genetic, biologic or environmental causes.
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One hundred twenty-three children from 6 French centers
were evaluated retrospectively for the treatment of steroid-
refractory acute graft-versus-host disease (aGVHD) with
Inolimomab, a murine anti-IL2R.Hematopoietic stem cell transplantations (HSCT) were
performed between 1995 and 2012. Diseases were non
malignant inherited diseases (63%) and hematological
malignancies (37%). Median age was 4, 3 years. Donors were
MRD (27.5%), MUD (32%), mismatch-MUD (13%), Haplo-
identical (20.5%) and Cord Blood (CB) (7%). The graft source
was BM (80%), PBSC (12%) and CB (8%). 37% patients had
a myeloablative conditioning. The median time to aGVHD
was 13 days after HSCT. The baseline grade of aGVHDwas I in
19%, II 45.5%, III 25% and IV 10.5%. The median delay between
aGVHD and Inolimomab was 16 days. The median dose was
0.4mg/kg and the median treatment duration of 27 days.
We observe 55% complete responses and 14% partial
responses for a total response rate of 69% and with no side
effect. Among the responders, 26% relapse. Incidence of
infection during treatment was 19.5%.
A logistic model on complete response provide evidence of
the highpredictive negative effect of the baseline grade [Odds
Ratio (OR): 5.24]. No particular target organwas a signiﬁcant
predictive factor for treatment response or survival. However,
multi-organ involvement predicted worse survival with 34%,
45% and 52% of death for patients with one, two, and three or
more organs involved, respectively (P ¼ .234).
The observed overall survival probability was 59%, with
a median survival time of 463 days. The Overall unadjusted
survivalswere 87%, 77 %, and61%at day 100, 200, andoneyear.
Survival was also signiﬁcantly improved for responders
(Relative Risk: 0.413; P ¼ .002).
As shown by multivariate Cox model, the survival was
signiﬁcantly lower for patients with non malignant inherited
diseases [Hazard Ratio (HR) ¼2.88, P < .001] compared with
hematological malignancies, and female patients were
associated with higher mortality (HR¼1.72 , P¼ .049). For
both response and survival, the success rates were signiﬁ-
cantly increasing with year of transplantation, and non-
signiﬁcant differences were found among centers.
Chronic GVHD (cGVHD) occurred in 56% patients, extensive
in 42%. cGVHD incidence was 78%, 72% , 42% for Non
Responders, Partial Responders and Complete Responders
(Anova, P¼ .017, difference only signiﬁcant between
Complete Responders and the others). Patients with hema-
tological malignancies were observed with signiﬁcantly less
cGHVD (OR¼.29, P¼ .012).
Fifty-one patients died, 17(33%) before day 100 and 34(67%)
after day 100, mostly of infections (55%) and GVHD (51%).
In conclusion, Inolimomab is well tolerated and effective for
steroid-refractory aGVHD in pediatrics. Further randomized
studies are requires to deﬁne the optimum regimen.
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